Long-term patient follow-up should be routinely implemented in radiotherapy units to detect late adverse effects after cancer treatment

Kirsti Aas; Amir Sherif

doi:10.2340/sju.v58.13470

Authors

Kirsti Aas Consultant Urological Surgeon and Associate Professor, Akershus University Hospital, Norway; Faculty of Medicine, University of Oslo, Norway
Amir Sherif Consultant Urological Surgeon and Associate Professor, Norrlands University Hospital, Sweden; Department of Surgical and Perioperative Sciences, University of Umeå, Sweden

DOI:

https://doi.org/10.2340/sju.v58.13470

Abstract

Editorial comment to Urosymphyseal fistula after pelvic radiotherapy – an entity in patients with significant comorbidity requiring multidisciplinary management Scand J Urol. 2023

Downloads

Download data is not yet available.

References

Moschini M, Zaffuto E, Karakiewicz PI, et al. External beam radiotherapy increases the risk of bladder cancer when compared with radical prostatectomy in patients affected by prostate cancer: A population-based analysis. Eur Urol. 2019;75(2):319–28. https://doi.org/10.1016/j.eururo.2018.09.034 DOI: https://doi.org/10.1016/j.eururo.2018.09.034

Guo X, Liu M, Hou H, et al. Impact of prostate cancer radiotherapy on the biological behavior and specific mortality of subsequent bladder cancer. Int J Clin Oncol. 2019;24(8):957–65. https://doi.org/10.1007/s10147-019-01427-9 DOI: https://doi.org/10.1007/s10147-019-01427-9

Zhao S, Xie Q, Yang R, et al. High prevalence of secondary bladder cancer in men on radiotherapy for prostate cancer: evidence from a meta-analysis. Cancer Manag Res. 2019;11:587–98. https://doi.org/10.2147/CMAR.S185867 DOI: https://doi.org/10.2147/CMAR.S185867

Martin SE, Begun EM, Samir E, Azaiza MT, Allegro S, Abdelhady M. Incidence and morbidity of radiation-induced hemorrhagic cystitis in prostate cancer. Urology. 2019;131:190–5. https://doi.org/10.1016/j.urology.2019.05.034 DOI: https://doi.org/10.1016/j.urology.2019.05.034

Makino K, Sato Y, Takenaka R, et al. Cumulative incidence and clinical risk factors of radiation cystitis after radiotherapy for prostate cancer. Urol Int. 2023;107(5):440–447. https://doi.org/10.1159/000521723 DOI: https://doi.org/10.1159/000521723

Carlsson S, Bock D, Lantz A, et al. Salvage radiotherapy after radical prostatectomy: functional outcomes in the LAPPRO trial after 8-year follow-up. Scand J Urol. 2023;58:11–9. https://doi.org/10.2340/sju.v58.7318 DOI: https://doi.org/10.2340/sju.v58.7318

Braide K, Kindblom J, Thellenberg Karlsson C, Stattin P, Hugosson J, Mansson M. Risk of severe late toxicity after radiotherapy following radical prostatectomy – a nationwide study. BJU Int. 2022;130(6):799–808. https://doi.org/10.1111/bju.15769 DOI: https://doi.org/10.1111/bju.15769

Fridriksson JO, Folkvaljon Y, Nilsson P, et al. Long-term adverse effects after curative radiotherapy and radical prostatectomy: population-based nationwide register study. Scand J Urol. 2016;50(5):338–45. https://doi.org/10.1080/21681805.2016.1194460 DOI: https://doi.org/10.1080/21681805.2016.1194460

David RV, Kahokehr AA, Lee J, Watson DI, Leung J, O’Callaghan ME. Incidence of genitourinary complications following radiation therapy for localised prostate cancer. World J Urol. 2022;40(10):2411–22. https://doi.org/10.1007/s00345-022-04124-x DOI: https://doi.org/10.1007/s00345-022-04124-x

Dearnaley D, Syndikus I, Mossop H, et al. Conventional versus hypofractionated high-dose intensity-modulated radiotherapy for prostate cancer: 5-year outcomes of the randomised, non-inferiority, phase 3 CHHiP trial. Lancet Oncol. 2016;17(8):1047–60. https://doi.org/10.1016/S1470-2045(16)30102-4 DOI: https://doi.org/10.1016/S1470-2045(16)30102-4

Lane JA, Donovan JL, Young GJ, et al. Functional and quality of life outcomes of localised prostate cancer treatments (Prostate Testing for Cancer and Treatment [ProtecT] study). BJU Int. 2022;130(3):370–80. https://doi.org/10.1111/bju.15739 DOI: https://doi.org/10.1111/bju.15739

Yu T, Zhang Q, Zheng T, et al. The effectiveness of intensity modulated radiation therapy versus three-dimensional radiation therapy in prostate cancer: a meta-analysis of the literatures. PLoS One. 2016;11(5):e0154499. https://doi.org/10.1371/journal.pone.0154499 DOI: https://doi.org/10.1371/journal.pone.0154499

Kerkmeijer LGW, Groen VH, Pos FJ, et al. Focal boost to the intraprostatic tumor in external beam radiotherapy for patients with localized prostate cancer: results from the FLAME randomized phase III trial. J Clin Oncol. 2021;39(7):787–96. https://doi.org/10.1200/JCO.20.02873 DOI: https://doi.org/10.1200/JCO.20.02873

Hamstra DA, Stenmark MH, Ritter T, et al. Age and comorbid illness are associated with late rectal toxicity following dose-escalated radiation therapy for prostate cancer. Int J Radiat Oncol Biol Phys. 2013;85(5):1246–53. https://doi.org/10.1016/j.ijrobp.2012.10.042 DOI: https://doi.org/10.1016/j.ijrobp.2012.10.042

David R, Hiwase M, Kahokehr AA, et al. Predicting post-radiation genitourinary hospital admissions in patients with localised prostate cancer. World J Urol. 2022;40(12):2911–8. https://doi.org/10.1007/s00345-022-04212-y DOI: https://doi.org/10.1007/s00345-022-04212-y